Literature DB >> 21879386

Delivery of brain-derived neurotrophic factor via nose-to-brain pathway.

Siva Ram Kiran Vaka1, Sathyanarayana Narasimha Murthy, Anna Balaji, Michael A Repka.   

Abstract

PURPOSE: To investigate the plausibility of delivering brain-derived neurotrophic factor (BDNF) to brain via nose-to-brain pathway using chitosan as barrier-modulating agent.
METHODS: Effect of different viscosity grades chitosan at different concentrations on permeation of fluorescein isothio-cyanate dextran (FD 40 K) across bovine olfactory mucosa was studied using Franz diffusion cells. Medium viscosity chitosan was used to carry out permeation studies of BDNF. Pharmacokinetic and pharmacodynamic studies were carried out in Sprague dawley rats upon intranasal/i.v administration of different formulations.
RESULTS: Medium viscosity chitosan more efficiently enhanced permeation of FD 40 K across olfactory mucosa compared to other grades. In case of BDNF, medium viscosity chitosan (0.25% w/v) enhanced permeation ~14-fold over control (18.78 ± 16.69 ng/cm(2)). Brain bioavailability of rats administered intranasally with BDNF solution containing chitosan was significantly enhanced ~13-fold compared to rats administered with same concentration of BDNF solution without chitosan. In rats subjected to immobilization stress, BDNF solution containing chitosan significantly decreased immobility time.
CONCLUSIONS: Intranasal formulations containing chitosan as barrier-modulating agent significantly enhanced brain bioavailability of BDNF. Delivery of BDNF was found to counteract stress-induced depression in rats.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879386      PMCID: PMC5650683          DOI: 10.1007/s11095-011-0572-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  40 in total

1.  Neuronal plasticity and survival in mood disorders.

Authors:  R S Duman; J Malberg; S Nakagawa; C D'Sa
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

Review 2.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

3.  Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts.

Authors:  P Tengamnuay; A Sahamethapat; A Sailasuta; A K Mitra
Journal:  Int J Pharm       Date:  2000-03-20       Impact factor: 5.875

4.  Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium.

Authors:  M C Schmidt; D Simmen; M Hilbe; P Boderke; G Ditzinger; J Sandow; S Lang; W Rubas; H P Merkle
Journal:  J Pharm Sci       Date:  2000-03       Impact factor: 3.534

5.  Effects of adverse experiences for brain structure and function.

Authors:  B S McEwen
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

6.  The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death.

Authors:  R M Sapolsky
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

7.  Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.

Authors:  J H Kordower; S Palfi; E Y Chen; S Y Ma; T Sendera; E J Cochran; E J Cochran; E J Mufson; R Penn; C G Goetz; C D Comella
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

8.  Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus.

Authors:  M A Smith; S Makino; R Kvetnansky; R M Post
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

Review 9.  Neurotrophins and neurodegeneration.

Authors:  D Dawbarn; S J Allen
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

10.  Loss of developing cholinergic basal forebrain neurons following excitotoxic lesions of the hippocampus: rescue by neurotrophins.

Authors:  M A Burke; W C Mobley; J Cho; S J Wiegand; R M Lindsay; E J Mufson; J H Kordower
Journal:  Exp Neurol       Date:  1994-12       Impact factor: 5.330

View more
  16 in total

1.  Intranasal Delivery of Recombinant NT4-NAP/AAV Exerts Potential Antidepressant Effect.

Authors:  Xian-Cang Ma; Zheng Chu; Xiao-Ling Zhang; Wen-Hui Jiang; Min Jia; Yong-Hui Dang; Cheng-Ge Gao
Journal:  Neurochem Res       Date:  2016-02-04       Impact factor: 3.996

Review 2.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

3.  Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.

Authors:  Chun Xiao; Francesca J Davis; Balwantsinh C Chauhan; Kirsten L Viola; Pascale N Lacor; Pauline T Velasco; William L Klein; Neelima B Chauhan
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 4.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

5.  In Vitro Modulation of TrkB Receptor Signaling upon Sequential Delivery of Curcumin-DHA Loaded Carriers Towards Promoting Neuronal Survival.

Authors:  Luis P B Guerzoni; Valérie Nicolas; Angelina Angelova
Journal:  Pharm Res       Date:  2016-12-19       Impact factor: 4.200

6.  Nanoformulation of Brain-Derived Neurotrophic Factor with Target Receptor-Triggered-Release in the Central Nervous System.

Authors:  Yuhang Jiang; James M Fay; Chi-Duen Poon; Natasha Vinod; Yuling Zhao; Kristin Bullock; Si Qin; Devika S Manickam; Xiang Yi; William A Banks; Alexander V Kabanov
Journal:  Adv Funct Mater       Date:  2017-12-07       Impact factor: 18.808

7.  Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model.

Authors:  Robin Ji; Morgan Smith; Yusuke Niimi; Maria E Karakatsani; Maria F Murillo; Vernice Jackson-Lewis; Serge Przedborski; Elisa E Konofagou
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

8.  Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder.

Authors:  Xian-cang Ma; Peng Liu; Xiao-ling Zhang; Wen-hui Jiang; Min Jia; Cai-xia Wang; Ying-ying Dong; Yong-hui Dang; Cheng-ge Gao
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

Review 9.  Nerve Growth Factor: A Focus on Neuroscience and Therapy.

Authors:  Luigi Aloe; Maria Luisa Rocco; Bijorn Omar Balzamino; Alessandra Micera
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

10.  A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats with Post-Stroke Depression.

Authors:  Ce Chen; Yingying Dong; Fei Liu; Chengge Gao; Cui Ji; Yonghui Dang; Xiancang Ma; Yong Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.